- The Medicines and Healthcare products Regulatory Agency (MHRA) authorized the vaccine - made by Pfizer Inc PFE and BioNTech SE BNTX for children aged six months to four years old.
- This decision was endorsed after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants.
- The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years.
- Related: Pfizer/BioNTech's Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages.
- It is given as three injections in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.
- This presentation is designed for this new age group and given at a lower dose than those used in individuals aged 5 to 11 years (3 micrograms compared with 10 micrograms).
- The Comirnaty COVID vaccine has met the MHRA's required safety, quality, and effectiveness standards to be authorized for use in this age group.
- Price Action: PFE shares are down 2.38% at $49.53, and BNTX shares are down 3.96% at $160.10 on the last check Monday.
- Photo via Wikimedia Commons
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.